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Abstract: FLT3 (fms-related tyrosine kinase 3) is a receptor tyrosine kinase class III that 
is expressed on by early hematopoietic progenitor cells and plays an important role in 
hematopoietic stem cell proliferation, differentiation and survival. FLT3 is also expressed 
on leukemia blasts in most cases of acute myeloid leukemia (AML). In order to 
determine the frequency of FLT3 oncogene mutations, we analyzed genomic DNA of 
adult de novo acute myeloid leukemia (AML). Polymerase chain reaction (PCR) and 
conformation-sensitive gel electrophoresis (CSGE) were used for FLT3 exons 11, 14, and 
15, followed by direct DNA sequencing. Two different types of functionally important 
FLT 3 mutations have been identified. Those mutations were unique to patients with 
inv(16), t(15:17) or t(8;21) and comprised fifteen cases with internal tandem duplication  
(ITD) mutation in the juxtamembrane domain and eleven cases with point mutation (exon 
20, Asp835Tyr). The high frequency of the flt3 proto-oncogene mutations in acute 
myeloid leukemia AML suggests a key role for the receptor function.  The association of 
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FLT3 mutations with chromosomal abnormalities invites speculation as to the link 
between these two changes in the pathogenesis of acute myeloid leukemiaAML. 
Furthermore, CSGE method has shown to be a rapid and sensitive screening method for 
detection of nucleotide alteration in FLT3 gene. Finally, this study reports, for the first 
time in Saudi Arabia, mutations in the human FLT3 gene in acute myeloid leukemia 
AML patients.  
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1. Introduction 
 
The FLT3 gene (fms-like tyrosine kinase), is a member of the class III tyrosine kinase receptor 
family that includes c-kit, c-fms and the platelet-derived growth factor receptors (PDGFRs) [1-3]. 
Class III receptor tyrosine kinases (RTKs) share sequence homology and have a similar overall 
structure, with five immunoglobulin-like repeats in the extracellular domain, a single transmembrane 
domain (TM), a juxtamembrane domain (JM), two intracellular tyrosine kinase domains (TK1 and 
TK2) divided by a kinase insert domain (KI), and a C-terminal domain [4]. The genomic locus 
encoding the FLT3 receptor has recently been shown to comprise 24 rather than the expected 21 
exons, ranging 83-562 bp [5]. Data from different sources suggest a pathogenic role of FLT3 in acute 
myeloid leukemia (AML). Hence functional analysis of FLT3 expression has been documented in 
many cases of AML, besides of immortalized human myeloid and monocytic cell lines [3, 6-8]. The 
ITD and activation loop mutations of the receptor have resulted in the constitutive FLT3 kinase 
activity and FLT3 receptors harboring such mutations when introduced into mammalian cells 
downstream signaling pathways lead to factor-independent growth in vitro and leukemogenesis in vivo 
[9, 10]. Thus the production of FLT3 mutant protein in primary murine bone marrow cells induces a 
lethal myeloproliferative phenotype [11]. It is known that FLT3 is a leukemia oncogene and activating 
FLT3 mutations are likely to contribute in the development of leukemia in humans. 
In addition, several small molecule inhibitors have also been implicated in blocking the kinase 
activity of FLT3 effectively [11-14]. These can prolong the life span of mice harboring leukemia 
expressing mutant FLT3 receptors [11, 15]. In clinical trials, FLT3 inhibitors reduced FLT3 
phosphorylation [16-18], and lowered leukemia blast counts in patients with advanced therapy-
refractive AML [18, 19]. 
Until now, no study has reported the frequency and prevalence of FLT3 mutations in AML patients 
in the Kingdom of Saudi Arabia. This study was conducted with that objective in mind and was 
therefore undertaken using polymerase chain reaction-conformation sensitive gel electrophoresis 
(PCR-CSGE) on DNA extracted from archival bone marrow of Saudi AML patients. 
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2. Results and Discussion 
 
2.1. Detection of the FLT3-ITD mutation 
 
In order to screen for the FLT3-ITD mutation, exons 14 and 15 of the FLT3 gene were amplified 
from genomic DNA of 129 AML patients using PCR, followed by conformation sensitive gel 
electrophoresis (CSGE) analysis.  Abnormal CSGE patterns in 15 AML patients were identified in 
PCR fragments and the remaining patients reported no such patterns. These abnormal patterns, shown 
in Figure 1, were due to conformational changes occurred in the gel indicating nucleotide alteration 
(in-frame insertion mutation) within the PCR fragment. When direct DNA sequencing analysis was 
carried out on all 15 AML cases with abnormal CSGE patterns, ITD mutations were detected in all 
cases with lengths varying between 24-60 bp. The FLT3-ITD mutations detected included either a part 
or whole stretch of tyrosine-rich sequence of the FLT3 gene located between codons 589-599 (Figure 
2). Furthermore, these mutations were located in-frame of the JM domain of FLT receptor which gave 
the evidence of tandem duplications, thus confirming the ITD in the samples. 
 
Figure 1. CSGE analysis of exons 14 and 15 PCR product amplified from AML patients. 
CSGE gel demonstrating abnormal patterns (indicated by arrowheads) compared to normal 
pattern (lane N, PCR product amplified from healthy individual, indicated by arrow). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2. Detection of the Asp835Tyr mutation 
 
In addition to the FLT3-ITD mutation, the Asp835Tyr mutation is also prevalent in AML cases.  To 
screen our cohort for the presence of this mutation, exon 20 of the FLT3 gene was subjected to PCR-
CSGE followed by direct sequencing in all 129 AML cases.  Eleven cases of AML (8.5%) exhibited 
an abnormal CSGE pattern (Figure 3), and sequencing revealed a G to C mutation in codon 
Asp835Tyr (Figure 4). Six of these were classified as AML M4, four of which demonstrated inv(16). 
In addition, FLT3 ITD mutations were identified in 15 patients; however, no case possessed both an 
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ITD and Asp835 mutation jointly. The detailed clinical characteristics of AML patients forming the 
basis of this observation are summarized in Table 1. 
 
Figure 2. Sequence analysis of exons 14 and 15 of FLT3 gene. Inserted nucleotides for 
tandem duplications of the Flt3 gene observed in AML cases with apparent CSGE patterns. 
 
Wild type 
Codon 
Nucleotides 
Amino acid 
 
581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 
gtg acc ggc tcc tca gat aat gag tac ttc tac gtt gat ttc aga gaa tat gaa tat gat ctc aaa tgg gag 
 V   T   G   S   S   D   N   E   Y   F   Y   V   D   F   R   E   Y   E   Y   D   L   K   W   E 
Case 5 
Nucleotides 
Amino acid 
 
        ggc tcc tca gat aat gag tac ttc gac tac gtt gat ttc aga gaa tat gaa 
         G   S   S   D   N   E   Y   F   D   Y   V   D   F   R   E   Y   E 
Case 28 
Nucleotides 
Amino acid 
 
    acc ggc tcc tca gat gag aat aat gag tac ttc tac gtt gat ttc aga gaa tat gaa tat gat ctc aaa  
     T   G   S   S   D   V   N   N   E   Y   F   Y   V   D   F   R   E   Y   E   Y   D   L   K 
Case 57 
Nucleotides 
Amino acid 
 
gtg acc ggc aac tcc tca gat aat gag tac ttc tac gtt gat ttc aga gaa tat gaa tat gat ctc aaa 
 V   T   G   N   S   S   D   N   E   Y   F   Y   V   D   F   R   E   Y   E   Y   D   L   K 
*Small letters indicate nucleotides sequences and capital letters indicate amino acids sequences. 
*In-frame insertion mutations indicated by bold letter. 
 
Figure 3. CSGE analysis of exon 20 of FLT3 gene demonstrating abnormal CSGE pattern 
compared to that seen in a normal individual (Lane N). 
 
 
 
 
 
 
Figure 4. Point mutation in exon 20 of FLT 3 gene in AML cases detected by direct DNA 
sequence analysis. Mutated nucleotides are represented by changed amino acid, (bold). 
 
 
 
 
 
 
FAB: French-American-British. ITD: Internal Tandem Duplication. 
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Homoduplex 
            830 831 832 833 834 835 836 837 838 839 840 
Normal      Phe Gly Leu Ala Arg Asp Ile Met Ser Asp Ser 
         5’ TTT GGA TTG GCT CGA GAT ATC ATG AGT GAT TCC 3’ 
Abnormal    Phe Gly Leu Ala Arg Tyr Ile Met Ser Asp Ser 
         5’ TTT GGA TTG GCT CGA CAT ATC ATG AGT GAT TCC 3’ Int. J. Mol. Sci. 2008, 9 
 
Table 1. Clinical characteristics of AML cases and accompanied mutations. 
Case no.  Age (years)  Sex FAB subtype Karyotype  Mutations 
5 73  F  M3  46;XY,  t(15;17) ITD 
7 32  M  M3  46;XY,  t(15;17) ITD 
9 48  F  M3  46;XY,  t(15;17) ITD 
12 51  F  M2  46;XY,  t(8;21)  ITD 
18 24  F  M3  46;XY,  t(15;17) ITD 
20 62  F  M3  46;XY,  t(15;17) ITD 
23 32  M  M4  46;XY,  inv(16)  ITD 
25 33  M  M4  46;XY,  inv(16)  ITD 
28 38  M  M3  46;XY,  t(15;17) ITD 
29 46  F  M2  46;XY,  t(8;21)  ITD 
41 48  M  M3  46;XY,  t(15;17) ITD 
44 62  F  M3  46;XY,  t(15;17) ITD 
49 64  F  M4  46;XY,  inv(16)  ITD 
53 43  F  M2  46;XY,  t(8;21)  ITD 
58 49  M  M3  46;XY,  t(15;17) ITD 
64  48  M  M4  46;XY, inv(16)  Asp 835 Tyr 
69  47  M  M4  46;XY, inv(16)  Asp 835 Tyr 
80  34  M  M4  46;XY, inv(16)  Asp 835 Tyr 
83  39  M  M2  46;XY, t(8;21)  Asp 835 Tyr 
91  37  M  M2  46;XY, t(8;21)  Asp 835 Tyr 
96  38  F  M6  46;XY  Asp 835 Tyr 
108  35  F  M5  46;XY  Asp 835 Tyr 
116  31  F  M1  46;XY  Asp 835 Tyr 
118  33  F  M4  46;XY  Asp 835 Tyr 
121  25  M  M2  46;XY, inv(16)  Asp 835 Tyr 
128  45  F  M6  46;XY  Asp 835 Tyr 
 
2.3. Analysis of correlation with survival 
 
Survival analysis was calculated using Kaplan-Meier plot for comparison between Asp835Tyr and 
ITD AML patients. The survival curves were plotted for AML patients with Asp 835 mutation (n = 11) 
and ITD mutations (n = 15). The Mantel-Cox test demonstrated that the difference between the two 
groups of AML patients was not statistically significant (Figure 5).  
We undertook in this study the analysis of ITD and Asp 835 mutations of the FLT3 gene in Saudi 
AML patients in order to better understand the prevalence of these mutations in our cohort of cases. 
FLT3-ITD mutation is thought to cause the constitutive and ligand-independent activation of the 
receptor, but Fenski et al. [20] have shown that FLT3 oncogene is constitutively activated in 3/18 
cases of AML patients and only 1/3 of those cases exhibited the FLT3-ITD mutation.  It was therefore 
suggested that some other mechanisms are operational for the activation of the receptor, either because Int. J. Mol. Sci. 2008, 9 
 
of mutations elsewhere in the gene or due to autocrine mechanisms. This prompted us to include in our 
screen exon 20 and identify mutations involving Asp 835. Previous studies indicated that Asp 835 
highly conserved homologues, are probably playing a crucial role in the function of the activating loop 
of the JM region and kinase domain of class III RTKs [20-26].  The frequency of FLT3-ITD mutation 
identified in this study is much lower than reported for other ethnic populations which range between 
20%-25% in Japanese [27], Chinese [28], Thai [29] or German [30] populations.  It is interesting to 
find that all the detected cases of FLT3-ITD mutations exhibited cytogenetic aberrations, in particular 
t(15;17), t(8;21) and Inv(16).  These chromosomal rearrangements are commonly found in adult AML 
cases as in our cohort inv(16) is the most common event at 26.3%, followed by the presence of 
t(15;17) translocation (17.8%).  The t(8;21) translocation constituted only 8.5% of the cases in our 
cohort.  The FLT3-ITD mutations were all detected in cases with cytogenetic translocations.  Whether 
this reflects a case of global genomic instability or not is unknown.  Screening of a larger cohort of 
samples may shed some light into the potential association between FLT3-ITD mutations and   
genomic instability. 
 
Figure 5. Kaplan-Meier cumulative survival analysis for AML patients with Asp 835 and 
ITD mutations and AML patients without mutations. Blue line indicates patients with Asp 
835 mutation, red line indicates patients with ITD mutations and green line patients 
without flt3 mutations. The survival analysis showed no significance differences between 
the three groups (p = 0.15). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The first aim of this study was to screen the FLT3 gene for previously reported mutations in AML 
using a sensitive and simple method to determine the frequency of the mutations.  Efficiency and 
sensitivity were the main criteria to be considered in the selection of the method of mutation detection 
to be used in the analysis of the FLT3 gene. CSGE was the method of choice for screening the FLT3 
gene because of its high sensitivity and simplicity as reviewed by Ganguly  [31].  The technique has 
been used in different studies for the analysis of factor VIII gene in hemophilia A patients [32-33] and 
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other genes including the von Willebrand factor (VWF) gene [34], factor IX [35].  For example, the 
sensitivity of CSGE in the detection of mutations was 100% in 21 hemophilia B patients [35] and 88% 
in patients with VWD [34].  Moreover, CSGE was selected as the method of choice to ensure all 
previously known FLT3 mutations can be detected.  
 
3. Conclusions 
 
In conclusion, we report mutations in the human FLT3 gene in a cohort of Saudi AML patients. 
These mutations are likely to lead to constitutive activation of the FLT3 receptor.  The FLT3-ITD 
mutation rates reported in this study are lower than expected which would justify that future studies 
will need to screen the complete coding and regulatory sequence of the FLT3 gene to determine 
whether additional mutations are associated with the pathogenesis of myeloid malignancy.  
 
4. Experimental Section 
 
4.1. Patient DNA samples 
 
Sample DNA was collected from 129 routinely-processed unstained bone marrow slides diagnosed 
as Acute myeloid leukemia (AML), which had been stored in a box at room temperature in an air-
conditioned storage room for up to 20 years (from 1987 to 2007) in the archives of Hematology 
Laboratory at King Abdulaziz University Hospital. Genomic DNA was extracted (as optimized by 
Gari, et al. [36]) from the scraped material of each bone marrow slide using the Nucleon
™ BACC1 
DNA extraction kit (Nucleon Biosciences). Theses samples of genomic DNA were selected at 
presentation from 129 cases of AML (53 women, 76 men, and mean age 40.3 years, range 22-65). The 
cases were classified according to the FAB criteria [37] as M0 (n = 5), M1 (16), M2 (n = 38), M3 (n = 
23), M4 (n = 34), M5 (n = 9) and M6 (n = 4). Sixty-eight patients had good risk and 61 had 
intermediate risk disease, as defined by standard cytogenetic analysis [38]; inv(16) (n = 34), t(15;17) 
(n = 23) and t(8;21) (n = 11).  
 
4.2. Genomic DNA amplification 
 
DNA amplification was performed by polymerase chain reaction (PCR).  All exons, and 
intron/exon boundaries of the FLT3 gene involved in this study were amplified independently. The 
entire coding sequence and intron/exon boundaries corresponding to exons 14, 15 (ITD) and 20 
(Asp835) of the FLT3 gene were amplified independently, using oligonucleotide primers as shown in 
Table 2. 
The PCR reactions contained the following: genomic DNA (500 ng), (NH4)2SO4 (16.6 mM), Tris 
HCL (pH 8.0, 67 mM), β-mercaptoethanol (10 mM), bovine serum albumin (BSA, 100 μg), each 
primer (300 ng), dNTPs (200 μM), MgCl2 (1.50 mM), and Taq DNA polymerase (1 U) in a final 
volume of 50 μL. Samples were initially denatured at 94°C for 5 minutes.  DNA amplification was 
performed by 35 cycles of denaturation at 94°C for 1 minute, annealing at 55
° C for 30 second and Int. J. Mol. Sci. 2008, 9 
 
extension at 72 °C for 30 second.  Five μL of each PCR products was loaded onto 5% polyacrylamide 
gel or agarose gel to ensure the amplification had occurred.  
 
Table 2. Oligonucleotide primers used in PCR analysis. 
    Primer sequences  Fragment size (bp) 
ITD 
F 
R 
5′-TCTGTTTCATCGCTGAGTGAC-3′ 
5′-AGCCTTGAAACATGGCAAAC-3′ 
396 
Exon 20 
F 
R 
5′-CCAGGAACGTGCTTGTCA-3′ 
5′-TCAAAAATGCACCACAGTGAG-3′ 
352 
F: forward; R: reverse. 
 
4.3. Mutation detection 
 
Conformation sensitive gel electrophoresis (CSGE) was used to screen for mutations as described 
in [31]. Briefly, PCR products were denatured by heating to 95°C for 5 minutes and then incubated at 
65°C for 30 minutes.  These PCR products were resolved on 10% polyacrylamide gels; 99:1 ratio 
acrylamide (BDH):bis-acrolypiperazine (BAP; Fluka), 10% ethylene glycol (Sigma), 15% formamide 
(Sigma) and 0.5 × TTE buffer (1 × TTE =  89 mM Tris, 28.5 mM taurine, 0.2 mM EDTA).  Samples 
displaying abnormal CSGE profiles compared to that obtained from a normal individual were directly 
sequenced using automated DNA sequencer (API 310 prizm). 
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